Actively Recruiting
Testing BI 764198 Tablets for Adults and Adolescents with Various Proteinuric Kidney Diseases Compared to Placebo
Led by Boehringer Ingelheim · Updated on 2026-10-28
132
Participants Needed
154
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the medicine BI 764198 to see if it helps people with certain kidney conditions, including secondary focal segmental glomerulosclerosis, treatment-resistant primary minimal change disease, Alport Syndrome, and treatment-resistant primary membranous nephropathy. The study includes adults and adolescents with specific kidney diseases and aims to assess the medicines safety, tolerability, and effectiveness compared to a placebo. Participants are randomly assigned to one of two groups one group takes BI 764198 tablets and the other takes placebo tablets that look identical but do not contain medicine. They take one tablet daily for 20 weeks while continuing their usual kidney disease treatments. The chance of being assigned to the BI 764198 group is twice as high as being assigned to the placebo group. The study lasts about 7 months, during which participants attend six site visits and three phone calls. Doctors regularly collect urine and blood samples to measure protein levels and kidney function. They monitor health and any side effects, comparing results between the groups to evaluate the treatment. The primary outcome is the change in urine protein-to-creatinine ratio after 20 weeks.
CONDITIONS
Brief Title
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here